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   Diabetes mellitus has been increasing worldwide, 
and become a crucial challenge to maintain and 
promote the health of people [1]. Since Type 2 diabetes 
mellitus (T2DM) shows marked heterogeneity in 
clinical symptoms, sign, various risk factors, 
multifactorial outcome, and course, the management 
cannot be conducted by an individualized approach 
[2]. If there are some subgroups in T2DM, adequate 
treatment suitable to each patient can be provided with 
more effectiveness and less cost [3].   
 
    Conventionally, type 1 diabetes mellitus (T1DM) may 
be classified according to the positive islet-related 
autoantibodies or presence of autoimmunity. However, 
it is usually categorized into three types according to 
the mode of onset. The three types are as follows: i) 
Fulminant onset type: insulin secretion is dramatically 
depleted as diabetic ketoacidosis develops within a few 
days after the onset [4], ii) Acute onset type: diagnosed 
as diabetic, such as diabetic ketoacidosis within a few 
months after the development of the dry mouth, 
polydipsia, polyuria, and weight loss, iii) Slowly 
progressive type: insulin secretion is not depleted at 
the time of diagnosis, and after a period of one year or 
more, insulin is depleted and insulin injection will be 
indispensable [5]. It has been called slowly-progressive 
insulin-dependent diabetes mellitus (SPIDDM) or 
Latent autoimmune diabetes in adults (LADA) [6,7]. 
 
Abstract 
    Diabetes includes various heterogeneous factors. Similar to subtypes of type 1 diabetes, type 2 diabetes may 
show four subtype clusters. They are cluster A: severe insulin-deficient diabetes, B: severe insulin-resistant 
diabetes, C: mild obesity-related diabetes, and D: mild age-related diabetes. Comparing them, the prevalence 
of nephropathy and cardiovascular events was highest in the cluster A. Reference data are i) the ratio of 
cluster A-D is 18.7%, 23.7%, 21.1%, 36.4%, ii) HbA1c for A-D is 11.05%, 8.17%, 8.49%, 7.95%, iii) event ratio 
of MACE is 14.4%, 10.6%, 11.4%, 9.1%. Future diabetic treatment is hopefully provided suitable for each 
subtype. 
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    On the other hand, T2DM has been different, and 
the concept of classifying into subtypes has hardly 
existed so far. It is often observed that patients with 
T2DM in Western countries (white and black) have 
obesity [8]. In contrast, T2DM patients in Asia (yellow 
race) seem to be non-obese. Consequently, it is rather 
useful for considering the subtype of T2DM because 
the background factors of T2DM are heterogeneous 
with a variety of different factors [9]. 
 
    There was an impressive study of T2DM in a large 
Swedish cohort study with adult-onset diabetes in 
2018 [10]. It was the All New Diabetes in Scania 
(ANDIS) cohort with 8980 individuals, using clustering 
on 6 available diabetes-associated variables, which are 
age at diagnosis, insulin secretory ability, insulin 
resistance, body mass index (BMI), HbA1c and islet-cell 
autoantibody. Four clusters were found resembling 
type 2 diabetes phenotypes, that was characterized by 
age at diagnosis, insulin resistance (calculated by 
homeostatic model assessment [HOMA]) and beta-cell 
function, BMI and HbA1c. There was the fifth cluster, 
which was defined by autoantibodies and was similar 
to autoimmune type 1 diabetes [10]. 
 
    Successively, a recent paper was reported in 2020 by 
Kahkoska et al., which shows the validation of distinct 
type 2 diabetes clusters [11]. The research is conducted 
by taking the most advantages of three 
cardiovascular outcomes trials (CVOT). These 
trials and number of subjects were DEVOTE 
(n=7637) [12], LEADER (n=9340) [13,14] and 
SUSTAIN-6 (n=3297) [15]. Clustering parameters were 
HbA1c, body mass index at baseline, and age at 
diabetes diagnosis. They analyzed the cumulative risk 
of a major adverse cardiovascular event (MACE), 
cardiovascular (CV) death and all-cause death by 
cluster in the DEVOTE, LEADER and SUSTAIN-6 trials. 
Using obtained data in three studies, subgrouping of 
T2DM were performed [11]. 
 
    Combined these findings of the research together, 
there were four cluster labels corresponding to the 
ANDIS labels [11]. The characteristic of the Cluster A-D 
are as follows: 
i) Cluster A, severe insulin-deficient diabetes; 
symptoms are rather severe, and GAD antibody 
 
   is negative. 
ii) Cluster B, severe insulin resistant diabetes; 
usually high value of body mass index (BMI). 
iii) Cluster C, mild obesity-related diabetes; more 
related with obesity status compared with the 
presence of insulin resistance.  
iv) Cluster D, mild age-related diabetes; the 
patients tend to develop the onset at older age 
than that of Cluster C.  
 
Among them, some important data are as follows: 
i) The ratio of cluster A-D in DEVOTE (n=7546) is 
18.7%, 23.7%, 21.1%, 36.4%, respectively. 
ii) HbA1c for A-D in LEADER is 11.05%, 8.17%, 
8.49%, 7.95%. 
iii) Event ratio for MACE for 2.5 years in DEVOTE 
seems to be 14.4%, 10.6%, 11.4%, 9.1%. 
iv) the ratio of new or worsening nephropathy in 
LEADER seems to be 12.6%, 4.9%, 8.8%, 
6.7%, respectively [11]. 
 
    In this study, the cases with positive islet-cell 
autoantibody were not included. Then, the number of 
subgroups was not five but four. When observing the 
results of HbA1c, BMI and age at diagnosis, data of 
median and 25%/75% quartiles were almost the same 
in three mega studies, and data of 4 clusters showed 
distribution apart [11]. This tendency suggests clinical 
significance for possible four clusters in T2DM. 
Comparing these four clusters, the prevalence of 
nephropathy and cardiovascular events (3-point 
MACE: non-fatal myocardial infarction, non-fatal 
stroke, cardiovascular death) was highest in the  
cluster A. 
 
    Related to these clusters, Dennis and collaborators 
have replicated the clusters of ANDIS for the clinical 
trials of ADOPT trial (n=4351) and RECORD (n=4447) 
[16]. The obtained data was similar to that of Ahlqvist 
et al., and these models based on simple clinical 
features seemed to be beneficial to stratify diabetic 
patients. Furthermore, Clustering study was 
performed in German Diabetes Association for patients 
with recent-onset diabetes (n=1105) [17]. The results 
showed i) mild age-related diabetes (MARD) 35%, ii) 
mild obesity-related diabetes (MOD) 29%, iii) severe 
autoimmune diabetes (SAID) 22%, iv)  severe   insulin- 
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resistant diabetes (SIRD) 11%, and v) severe insulin-
deficient diabetes (SIDD) 3%. Consequently, cluster 
analyses enable us to characterize cohort studies with 
different extent of insulin resistance for adipose tissue 
and whole body. These methods may lead to targeted 
prevention and treatment for diabetic precision 
medicine [17]). 
 
    Based on the above results, Kahkoska et al. 
suggested that the subtyping of the Swedish report 
would be appropriate and that each treatment method 
by subtype should be considered in the future  [11]. It 
is certain that cluster A (12.6 years in average) showed 
higher prevalence of arteriosclerosis and nephropathy 
than that of cluster C (21.2 years in average), 
indicating the difference and probable benefit among 4 
clusters categorization. 
 
    However, there are some limitations. Several 
situations may exist such as i) the same T2DM patients 
may have different characteristics in race, Europe, 
America, and Asia region, ii) the diabetic duration 
years may be influencing in addition to the age of 
onset, iii) judgment for clusters B or C may be difficult 
in the case of 50-year-old man with moderate obesity, 
and so on. 
 
    By accumulating various data, it is expected that the 
era will come in the future where treatment, 
management, and advice can be provided for each 
subtype cluster in T2DM. 
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